Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
ProShares Ultra Bloomberg Crude Oil ETF
UCO
5
United Sts Brent Oil Fd Lp Unit
BNO
GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.